{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061609","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.243250+00:00","generated_at":"2026-06-01T22:48:57.948949+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sagimet Q1 2024 net loss $6.6M; cash $193.7M; FDA End-of-Phase 2 meeting in Q2; MASH Phase 3 start H2","bullets":["Net loss for Q1 2024 was $6.6M, flat year-over-year; R&D expense $5.3M, G&A $3.5M.","Cash, cash equivalents and marketable securities total $193.7M as of March 31, 2024, expected to fund operations through 2025.","Denifanstat Phase 2b FASCINATE-2 full data to be presented as oral at EASL June 5-8, 2024.","End-of-Phase 2 meeting with FDA anticipated in Q2 2024; Phase 3 trial start planned for second half of 2024.","Follow-on offering in January 2024 netted $104.7M to support pipeline and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061609","json":"https://secwatch.observer/filing/0001104659-24-061609.json","markdown":"https://secwatch.observer/filing/0001104659-24-061609.md","text":"https://secwatch.observer/filing/0001104659-24-061609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/0001104659-24-061609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/tm2414482d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:48:57.948949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0f4d6ff9965575167ab173d8de615fa9ff9bb62","claim":"Sagimet Biosciences Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter ended March 31, 2024 was $6.6 million compared to a net loss of $6.6 million for the firs.","evidence_excerpt":"today reported financial results for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/0001104659-24-061609-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter ended March 31, 2024 was $6.6 million compared to a net loss of $6.6 million for the firs"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}